Skip to main content

Profile

Loading content
Dr Katie Young

Dr Katie Young

Postdoctoral Research Associate

 

Overview

Katie is a Postdoctoral Research Associate in Health Data Science, working in Professor Andrew Hattersley’s diabetes research team.

Previously Katie worked as a Research Data Coordinator within the team, working with the data from UK Biobank (particularly primary care records) to identify prevalent and incident cases of diabetes.

In her current role she is working with Dr John Dennis on stratified medicine in Type 2 diabetes, using primary care data from the Clinical Practice Research Datalink (CPRD).

Qualifications

  • PhD in Biophysics (University of Oxford)
  • MBiochem Biochemistry (University of Oxford)

Research

Research interests

  • Primary care record usage in research
  • Type 2 diabetes
  • Stratified / personalised medicine

Publications

Key publications | Publications by category | Publications by year

Key publications


Young KG, McDonald TJ, Shields BM (In Press). Glycated haemoglobin measurements from UK Biobank are different to those in linked primary care records: implications for combining biochemistry data from research studies and routine clinical care.  Abstract.
Hagenaars SP, Gillett AC, Casanova F, Young KG, Green H, Lewis CM, Tyrrell J (In Press). The impact of depression diagnosis on diabetes and lifetime hyperglycaemia.  Abstract.
Green HD, Young KG, Jones AG, Weedon MN, Dennis JM (In Press). Using joint models to adjust for informative drop-out when modelling a longitudinal biomarker: an application to type 2 diabetes disease progression.  Abstract.
Dennis JM, Young KG, McGovern AP, Mateen BA, Vollmer SJ, Simpson MD, Henley WE, Holman RR, Sattar N, Pearson ER, et al (2022). Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. The Lancet Digital Health, 4(12), e873-e883.
Thomas NJ, McGovern A, Young KG, Sharp SA, Weedon MN, Hattersley AT, Dennis J, Jones AG (2022). Identifying type 1 and 2 diabetes in research datasets where classification biomarkers are unavailable: assessing the accuracy of published approaches. Journal of Clinical Epidemiology
Gilchrist M, Casanova F, Tyrrell JS, Cannon S, Wood AR, Fife N, Young K, Oram RA, Weedon MN (2022). Prevalence of Fabry disease-causing variants in the UK Biobank. Journal of Medical Genetics Abstract.

Publications by category


Journal articles

Young KG, McDonald TJ, Shields BM (In Press). Glycated haemoglobin measurements from UK Biobank are different to those in linked primary care records: implications for combining biochemistry data from research studies and routine clinical care.  Abstract.
Dennis JM, Young KG, McGovern AP, Mateen BA, Vollmer SJ, Simpson MD, Henley WE, Holman RR, Sattar N, Pearson ER, et al (2022). Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. The Lancet Digital Health, 4(12), e873-e883.
Thomas NJ, McGovern A, Young KG, Sharp SA, Weedon MN, Hattersley AT, Dennis J, Jones AG (2022). Identifying type 1 and 2 diabetes in research datasets where classification biomarkers are unavailable: assessing the accuracy of published approaches. Journal of Clinical Epidemiology
Gilchrist M, Casanova F, Tyrrell JS, Cannon S, Wood AR, Fife N, Young K, Oram RA, Weedon MN (2022). Prevalence of Fabry disease-causing variants in the UK Biobank. Journal of Medical Genetics Abstract.
Young KG, McGovern AP, Barroso I, Hattersley AT, Jones AG, Shields BM, Thomas NJ, Dennis JM (2022). The impact of population-level HbA1c screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysis. Diabetologia Abstract.
Heald AH, Martin S, Fachim H, Green HD, Young KG, Malipatil N, Siddals K, Cortes G, Tyrrell J, Wood AR, et al (2021). Genetically defined favourable adiposity is not associated with a clinically meaningful difference in clinical course in people with type 2 diabetes but does associate with a favourable metabolic profile. Diabetic Medicine, 38(9).
Young KG, Najafi B, Sant WM, Contera S, Louis AA, Doye JPK, Turberfield AJ, Bath J (2020). Reconfigurable T‐junction DNA Origami. Angewandte Chemie, 132(37), 16076-16080.

Conferences

Young KG, Hopkins R, Thomas NJ, Shields BM, Dennis JM, McGovern AP (2022). Current rates of sodium-glucose link transporter 2 inhibitors (SGLT2i) prescribing in type 2 diabetes show no evidence of prioritisation in those with cardiovascular disease and heart failure.  Author URL.
Hopkins R, Godwin J, Young KG, Mateen BA, Vollmer SJ, Thomas NJ, Shields BM, McGovern AP, Dennis JM (2022). In people with type 2 diabetes most risk factors for covid-19 mortality are shared with pneumonia, however ethnicity related risk is very different.  Author URL.
Hopkins R, Young KG, Godwin J, Raja D, Thomas NJ, Shields BM, Dennis JM, McGovern AP (2022). Modifiable risk factors including HbA(1c) and BMI are consistently associated with severe influenza, pneumonia, and Covid-19 infection outcomes in people with type 2 diabetes.  Author URL.
Young KG, McGovern AP, Hopkins R, Raya D, Sattar NA, Holman RR, Pearson ER, Hattersley AT, Jones AG, Shields BM, et al (2022). Precision medicine in type 2 diabetes: integrating trial and real-world evidence can provide accurate estimates of heart failure benefit when initiating SGLT2-inhibitors.  Author URL.
Tyrrell J, Gillett A, Casanova F, Young K, Green H, Lewis C, Hagenaars S (2022). The impact of depression. diagnosis on diabetes and lifetime hyperglycaemia. World Congress of Psychiatric Genetic (WCPG). 13th - 17th Sep 2022.
Gilchrist M, Casanova F, Tyrrell J, Fife N, Young K, Oram R, Weedon M (2021). MO042PREVALENCE OF FABRY DISEASE CAUSING VARIANTS IN THE UK BIOBANK.  Abstract.
Young KG, Dennis JM, Thomas NJ, Jones AG, McGovern A, Shields BM, Barroso I, Hattersley AT (2021). Participants with undiagnosed diabetes in UK Biobank wait on average two years to receive a diagnosis, and simple clinical features are associated with diagnosis delays.  Author URL.
Carr ALJ, Sharp SA, Young KG, Thomas NJ, Hattersley AT, Jones AG, Oram RA (2020). A type 1 diabetes genetic risk score is discriminative of adult-onset type 1 diabetes.  Author URL.
Young KG, Hill A, Tippett P, Knight BA, Hattersley AT, McDonald T, Shields BM, Thomas NJ, Jones AG, Grp SS, et al (2020). Adult-onset autoimmune diabetes has similar markers of severity and progression regardless of age of diagnosis, but is less likely to be managed intensively when diagnosed in older adults.  Author URL.
Young KG, Thomas NJ, Jones AG, McGovern A, Shields BM, Barroso I, Hattersley AT (2020). HbA(1c) screening in 195,460 'non-diabetic' individuals (40-69 years) identifies 1.1% with undiagnosed diabetes 2 years before clinical diagnosis.  Author URL.
Young K, Najafi B, Bath J, Turberfield A (2017). DNA T-junctions for studies of DNA origami assembly.

Publications by year


In Press

Young KG, McDonald TJ, Shields BM (In Press). Glycated haemoglobin measurements from UK Biobank are different to those in linked primary care records: implications for combining biochemistry data from research studies and routine clinical care.  Abstract.
Hagenaars SP, Gillett AC, Casanova F, Young KG, Green H, Lewis CM, Tyrrell J (In Press). The impact of depression diagnosis on diabetes and lifetime hyperglycaemia.  Abstract.
Green HD, Young KG, Jones AG, Weedon MN, Dennis JM (In Press). Using joint models to adjust for informative drop-out when modelling a longitudinal biomarker: an application to type 2 diabetes disease progression.  Abstract.

2022

Young KG, Hopkins R, Thomas NJ, Shields BM, Dennis JM, McGovern AP (2022). Current rates of sodium-glucose link transporter 2 inhibitors (SGLT2i) prescribing in type 2 diabetes show no evidence of prioritisation in those with cardiovascular disease and heart failure.  Author URL.
Dennis JM, Young KG, McGovern AP, Mateen BA, Vollmer SJ, Simpson MD, Henley WE, Holman RR, Sattar N, Pearson ER, et al (2022). Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. The Lancet Digital Health, 4(12), e873-e883.
Thomas NJ, McGovern A, Young KG, Sharp SA, Weedon MN, Hattersley AT, Dennis J, Jones AG (2022). Identifying type 1 and 2 diabetes in research datasets where classification biomarkers are unavailable: assessing the accuracy of published approaches. Journal of Clinical Epidemiology
Hopkins R, Godwin J, Young KG, Mateen BA, Vollmer SJ, Thomas NJ, Shields BM, McGovern AP, Dennis JM (2022). In people with type 2 diabetes most risk factors for covid-19 mortality are shared with pneumonia, however ethnicity related risk is very different.  Author URL.
Hopkins R, Young KG, Godwin J, Raja D, Thomas NJ, Shields BM, Dennis JM, McGovern AP (2022). Modifiable risk factors including HbA(1c) and BMI are consistently associated with severe influenza, pneumonia, and Covid-19 infection outcomes in people with type 2 diabetes.  Author URL.
Young KG, McGovern AP, Hopkins R, Raya D, Sattar NA, Holman RR, Pearson ER, Hattersley AT, Jones AG, Shields BM, et al (2022). Precision medicine in type 2 diabetes: integrating trial and real-world evidence can provide accurate estimates of heart failure benefit when initiating SGLT2-inhibitors.  Author URL.
Gilchrist M, Casanova F, Tyrrell JS, Cannon S, Wood AR, Fife N, Young K, Oram RA, Weedon MN (2022). Prevalence of Fabry disease-causing variants in the UK Biobank. Journal of Medical Genetics Abstract.
Tyrrell J, Gillett A, Casanova F, Young K, Green H, Lewis C, Hagenaars S (2022). The impact of depression. diagnosis on diabetes and lifetime hyperglycaemia. World Congress of Psychiatric Genetic (WCPG). 13th - 17th Sep 2022.
Young KG, McGovern AP, Barroso I, Hattersley AT, Jones AG, Shields BM, Thomas NJ, Dennis JM (2022). The impact of population-level HbA1c screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysis. Diabetologia Abstract.

2021

Heald AH, Martin S, Fachim H, Green HD, Young KG, Malipatil N, Siddals K, Cortes G, Tyrrell J, Wood AR, et al (2021). Genetically defined favourable adiposity is not associated with a clinically meaningful difference in clinical course in people with type 2 diabetes but does associate with a favourable metabolic profile. Diabetic Medicine, 38(9).
Gilchrist M, Casanova F, Tyrrell J, Fife N, Young K, Oram R, Weedon M (2021). MO042PREVALENCE OF FABRY DISEASE CAUSING VARIANTS IN THE UK BIOBANK.  Abstract.
Young KG, Dennis JM, Thomas NJ, Jones AG, McGovern A, Shields BM, Barroso I, Hattersley AT (2021). Participants with undiagnosed diabetes in UK Biobank wait on average two years to receive a diagnosis, and simple clinical features are associated with diagnosis delays.  Author URL.

2020

Carr ALJ, Sharp SA, Young KG, Thomas NJ, Hattersley AT, Jones AG, Oram RA (2020). A type 1 diabetes genetic risk score is discriminative of adult-onset type 1 diabetes.  Author URL.
Young KG, Hill A, Tippett P, Knight BA, Hattersley AT, McDonald T, Shields BM, Thomas NJ, Jones AG, Grp SS, et al (2020). Adult-onset autoimmune diabetes has similar markers of severity and progression regardless of age of diagnosis, but is less likely to be managed intensively when diagnosed in older adults.  Author URL.
Najafi B, Young KG, Bath J, Louis AA, Doye JPK, Turberfield AJ (2020). Characterising DNA T-motifs by Simulation and Experiment. Arxiv Abstract.
Young KG, Thomas NJ, Jones AG, McGovern A, Shields BM, Barroso I, Hattersley AT (2020). HbA(1c) screening in 195,460 'non-diabetic' individuals (40-69 years) identifies 1.1% with undiagnosed diabetes 2 years before clinical diagnosis.  Author URL.
Young KG, Najafi B, Sant WM, Contera S, Louis AA, Doye JPK, Turberfield AJ, Bath J (2020). Reconfigurable T‐junction DNA Origami. Angewandte Chemie, 132(37), 16076-16080.

2017

Young K, Najafi B, Bath J, Turberfield A (2017). DNA T-junctions for studies of DNA origami assembly.

Katie_Young Details from cache as at 2022-12-09 14:21:35

Refresh publications

Teaching

Supervision / Group

Back | Edit Profile